GRB7 and breast cancer: Though frequently amplified and over-expressed concurrently with HER-2 in breast cancers with chromosome 17q11-12 amplification, we and others have shown that GRB7 expression is an independent adverse prognostic factor for breast cancer, including the triple negative breast cancer subtype [9, 13, 14].